This Comprehensive Opioid Abuse Program (COAP) meeting advances and addresses one of the U.S. Attorney General’s priorities—heroin and opioid awareness—by supporting effective criminal justice policy, programs, information sharing, and collaborations within state, local, and tribal agencies and communities relating to mental illness and substance use. The purpose of the 2½-day COAP National Meeting is to bring together COAP grantees of all categories (approximately 200 grant sites), Prescription Drug Monitoring Program (PDMP) Administrators, Regional Substance Abuse Treatment (RSAT) providers, and other leaders and practitioners working to address the national opioid epidemic.
The COAP meeting, structured along tracks of critical subject expertise, will provide fundamental skills building and networking opportunities. Learning objectives for the meeting include effective interventions for substance abuse-related programs; promotion of cross-program collaboration and multidisciplinary team building; and sessions to address priority substance abuse-related topical and project-focused issues, including Medication-Assisted Treatment; strategic planning; sustainability; privacy law; public health and public safety partnerships; law enforcement diversion models; prescription drug monitoring; and peer support programs.
The strategic location of Washington, DC, was selected to facilitate the convening of a large audience from across the country as well as to allow for Bureau of Justice Assistance (BJA) leaders and staff (including drug policy personnel), federal partners, and national organizations to attend. The COAP meeting agenda will be composed of a mixture of plenaries, panel sessions, and workshops. Subject experts, federal officials, keynote speakers, and peer panels will address 800 administrators and practitioners from across the nation about the importance of combatting the opioid epidemic and the most innovative, effective, data-driven ways to do that.
In light of the mission and activities of this meeting, the criticality of this national epidemic, and the opportunity to address a priority of the U.S. Attorney General and the U.S. Department of Justice, we believe the benefit of this national-level event warrants the cost.
Please check the box next to the following questions if the answer is 'yes'.
Please enter the applicable Event Date if there is an Event associated with this TTA.
When entering an Event Date, the Time is also required.
If the TTA is targeted to a particular audience or location, please complete the questions below.
Milestones are an element, activity, work product, or key task associated with completing the TTA (e.g. kick-off meeting, collect data from stake holders, deliver initial data analysis).
Please complete the fields below, if applicable, to create a milestone for this TTA.
Please respond to the Performance Metrics below. The Performance Metrics questions are based on the TTA Type indicated in the General Information section of the TTA.
Please submit a signed letter of support from your agency’s executive or other senior staff member. The letter can be emailed to or uploaded with this request. The letter should be submitted on official letterhead and include the following information:
- General information regarding the request for TTA services, i.e., the who, what, where, when, and why.
- The organizational and/or community needs specific to the request for TTA services.
- The benefits or anticipated outcomes from the receipt of TTA services.
By submitting this application to BJA NTTAC, I understand that upon approval of this application for TTA, the requestor agrees to keep BJA NTTAC informed of any circumstances that may impact the delivery of the TTA, including changes in the date of the event, event cancellation, or difficulties communicating with the assigned TTA provider.
Please call [site:phone] if you need further assistance completing this application.